Gynecologic Oncology Update

HER2-Positive Gynecologic Cancers — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with Stage II uterine carcinosarcoma treated with surgery followed by paclitaxel/carboplatin, whole-pelvic radiation and vaginal cuff brachytherapy — Dr Angeles Alvarez Secord (0:00) Case: A woman in her mid 50s with ovarian cancer and a genomic instability score of 50, folate receptor alpha 90%, HER2 IHC 2+, and BRCA1/2 wild-type disease treated initially with surgery, carboplatin/paclitaxel and maintenance olaparib/bevacizumab — Dr Ursula Matulonis (8:46) CME information and select publications

• Chapters

HER2-Positive Gynecologic Cancers — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topics: Case: A woman in her mid 60s with metastatic serous endometrial carcinoma that is HER2 IHC 3+ who received first-line carboplatin/paclitaxel/trastuzumab and second-line trastuzumab deruxtecan — Ursula Matulonis, MD (0:00) Commentary: Role of HER2-directed therapy in the maintenance setting for patients with HER2-positive disease — Professor Jonathan A Ledermann (12:29) CME information and select publications

• Chapters

Ovarian and Endometrial Cancer — Proceedings from a Symposium Held in Conjunction with the American Oncology Network

Featuring perspectives from Dr Shannon N Westin and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics: Introduction (0:00) Ovarian Cancer (2:22) Endometrial Cancer (37:48) CME information and select publications

• Chapters

Glucocorticoid Receptor Antagonists for Ovarian Cancer — An Interview with Professor Nicoletta Colombo

Featuring an interview with Professor Nicoletta Colombo, including the following topics: Mechanistic effects and rationale underlying the use of relacorilant/nab paclitaxel (0:00) Rationale underlying the study design of the Phase II BELLA trial and avenues for future exploration (8:31) Definition of platinum ineligibility; importance of platinum-containing chemotherapy for patients with ovarian cancer (14:02) Findings from a Phase II trial and the subsequent confirmatory Phase III ROSELLA study (20:25) Phase III ROSELLA study: Subgroup analyses, patient-reported outcomes, insights into overall survival data and common adverse events (29:43) Considerations for therapeutic selection and sequencing of novel therapies; ongoing and future investigations (38:46) CME information and select publications

HER2-Positive Gynecologic Cancers — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Featuring perspectives from Dr Joyce F Liu, Dr David M O'Malley and Dr Brian M Slomovitz, moderated by Dr O'Malley, including the following topic: Case: A woman in her late 50s with a BRCA1 germline mutation and platinum- and PARP inhibitor-resistant metastatic ovarian cancer with low folate receptor alpha level and HER2 IHC 1+ — Professor Jonathan A Ledermann CME information and select publications

Gynecologic Cancers — Reviewing Key Presentations from the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Gottfried E Konecny and Dr Brian M Slomovitz, including the following topics: Introduction (0:00) Preventing Ovarian Cancer (1:04) Endometrial Cancer (5:27) Ovarian Cancer (25:36) Cervical Cancer (54:04) CME information and select publications

• Chapters

Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00) Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03) Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failure on trametinib and then receives avutometinib/defactinib (16:15) Case: A woman in her mid 60s with recurrent BRAF V600E LGSOC has concerns about side effects and receives single-agent dabrafenib (19:49) CME information and select publications

• Chapters

Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1

Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00) A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11) Current and future role of avutometinib with defactinib for LGSOC (19:23) A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37) CME information and select publications

• Chapters

Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00) Adding a PARP inhibitor to immunotherapy and chemotherapy: The RUBY Part 2 and DUO-E trials (10:03) CME information and select publications

• Chapters

TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

Featuring an interview with Dr Ramez Eskander, including the following topics: Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00) Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53) Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58) Current and investigational targets of ADCs in gynecologic cancers (17:14) Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56) Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36) Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34) Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05) Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38) CME information and select publications

For Oncology Nurses: Ovarian Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Bradley J Monk, Dr David M O’Malley, Ms Kathryn M Schlenker and Ms Jaclyn Shaver, moderated by Dr O’Malley, including the following topics: Introduction (00:00) Overview of Ovarian Cancer (OC) (2:12) Role of PARP Inhibitors in Advanced OC (4:56) Current and Potential Future Role of Mirvetuximab Soravtansine in OC (28:45) Role of Relacorilant in Advanced OC (57:08) Utility of Immune Checkpoint Inhibition in Advanced OC (1:14:12) NCPD information and select publications

• Chapters

Endometrial Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Floor J Backes, Dr Brian M Slomovitz and Dr Shannon N Westin, moderated by Dr Westin, including the following topics: Introduction (00:00) Current Up-Front Chemoimmunotherapeutic Approaches for Advanced Endometrial Cancer (EC) — Dr Backes (1:50) Current and Future Role of Anti-PD-1/PD-L1 Antibodies in Combination with Systemic Therapies Beyond Chemotherapy for Advanced EC — Dr Westin (33:15) Promising Agents Under Investigation for EC — Dr Slomovitz (1:01:41) CME information and select publications

• Chapters

Ovarian Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

Featuring perspectives from Dr Ramez N Eskander, Dr Ursula Matulonis, Dr Kathleen N Moore, Dr Alexander B Olawaiye and Dr David M O'Malley, moderated by Dr Moore, including the following topics: Introduction (00:00) Current Role of PARP Inhibitors in the Management of Advanced Ovarian Cancer (OC) — Prof Eskander (2:40) Strategies Targeting Folate Receptor Alpha in Advanced OC — Dr Matulonis (27:41) Other Approved and Promising Investigational Antibody-Drug Conjugates for Advanced OC — Dr Moore (52:12) Other Novel Agents and Strategies for Advanced OC — Dr O'Malley (1:14:35) Diagnosis and Management of Adverse Events Associated with Common Therapies for Advanced OC — Dr Olawaiye (1:39:39) CME information and select publications

• Chapters

Endometrial Cancer — Microlearning Activity 2: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s presents with mismatch repair-deficient metastatic endometrial cancer(00:00) Perspectives on neoadjuvant immunotherapy for microsatellite instability-high endometrial cancer (06:25) CME information and select publications

• Chapters

Endometrial Cancer — Microlearning Activity 1: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women’s Cancer

Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 70s with de novo metastatic mismatch repair-proficient metastatic endometrioid endometrial cancer (00:00) Molecular analyses in the assessment and management of endometrial cancer (07:33) CME information and select publications

• Chapters

Endometrial Cancer — An Interview with Dr Floor J Backes

Featuring an interview with Dr Floor J Backes, including the following topics: Overview of the treatment landscape of endometrial cancer (00:00) Immunotherapy for advanced endometrial cancer (03:58) Contraindications for immunotherapy (18:15) PARP inhibitors for endometrial cancer (20:12) Management of localized endometrial cancer (28:23) Novel strategies under investigation for endometrial cancer (42:27) CME information and select publications

• Chapters

For Oncology Nurses: Strategies to Safely and Effectively Implement Antibody-Drug Conjugates — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Ms Courtney Arn, Ms Jamie Carroll, Dr Edward B Garon, Dr Heather McArthur and Dr Kathleen N Moore, moderated by Dr Moore, including the following topics: Introduction (0:00) Overview of Antibody-Drug Conjugates (ADCs) (2:07) Current and Future Role of HER2-Targeted ADCs for Breast Cancer (6:23) Currently Available ADCs for Gynecologic Cancer Management (26:37) Currently Available ADCs for Lung Cancer Management (44:07) Current and Future Role of TROP2-Targeted ADCs for Metastatic Breast Cancer (56:55) Other ADCs That May Soon Reach the Clinic for Advanced Gynecologic Cancers (1:15:07) Promising Investigational Strategies Employing ADCs for Lung Cancer (1:25:01) NCPD information and select publications

• Chapters

For Oncology Nurses: Endometrial Cancer — Proceedings from the 2026 Annual ONS Congress

Featuring perspectives from Dr Dana M Chase, Ms Sarah Karpen, Dr J Alejandro Rauh-Hain and Ms Jaclyn Shaver, moderated by Dr Chase, including the following topics: Introduction: Biology of Endometrial Cancer (EC) (0:00) First-Line Therapy for Advanced or Recurrent EC (14:15) Potential Benefits of PARP Inhibition Combined with Immunotherapy in Advanced EC (35:13) Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC (57:48) Other Nursing Considerations in the Care of Patients with Advanced EC (1:17:28) NCPD information and select publications

• Chapters

Ovarian Cancer — Fifth Annual National General Medical Oncology Summit

Featuring perspectives from Dr Deborah K Armstrong and Dr David M O’Malley, including the following topics: Introduction (0:00) PARP Inhibitors and Strategies Targeting Folate Receptor Alpha in Advanced Ovarian Cancer — Dr Armstrong (4:37) Other Novel Agents and Strategies for the Treatment of Advanced Ovarian Cancer — Dr O’Malley (35:18) CME information and select publications

• Chapters

HER2-Positive Gynecologic Cancers — Proceedings from a Session Held During the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancer

Featuring perspectives from Dr Joyce F Liu, Dr David M O’Malley and Dr Brian M Slomovitz, moderated by Dr O’Malley, including the following topics: Introduction (0:00) Strategies to Identify Patients with HER2-Positive Gynecologic Cancers — Dr Liu (2:52) Available Data with and Practical Application of HER2-Targeted Therapy in Advanced Gynecologic Cancers — Dr Slomovitz (25:16) Identification and Management of Adverse Events with Trastuzumab Deruxtecan — Dr O’Malley (1:00:31) CME information and select publications

• Chapters